←MRNAModernaOur view: UnattractiveFull analysisעברית
Updated 17 Nov 2026
The company · 1 · Who is this company?

Moderna makes vaccines from genetic instructions, called mRNA

COVID shots

93 cents of each sales dollar in 2025

A cancer vaccine

made with Merck for one patient at a time

Not yet approved

a US launch is planned for 2027

Moderna became famous for one of the two mRNA COVID vaccines. Sales have since collapsed, and the company's future now rests on a cancer vaccine built from each patient's own tumour.

The company · 2 · What exactly does it sell?

Seasonal shots today, a personalised cancer vaccine tomorrow

Each $1 of sales, by what is sold
93%7%1%
COVID-19 vaccines (Spikevax, mNEXSPIKE)Other revenueRSV vaccine (mRESVIA)

The vaccines are sold each autumn to governments, pharmacies and health systems. The cancer vaccine has no sales yet: it needs approval first.

The company · 3 · How does it make money?

Almost every dollar comes from COVID shots

Each $1 of sales in 2025
93 centsCOVID vaccines, Spikevax and mNEXSPIKE
Under 1 centthe RSV vaccine, mRESVIA
About 7 centsgrants, partners and fees for keeping plants ready

Most shots are bought in the autumn, so sales swing from quarter to quarter. If the cancer vaccine sells, Moderna and Merck split the costs and profit equally.

Is it a good business? · 4 · What gives it an edge?

It has the only personalised cancer vaccine that passed a large trial

42%fewer melanoma patients had cancer return or died, against Keytruda alone
1,137patients in the trial
12 yearsof US protection from copies once a medicine like this is approved

A rival would need its own years-long trial in each cancer. BioNTech's similar vaccine stopped its bowel cancer trial in August 2026.

Is it a good business? · 5 · What is the catch?

The vaccine business keeps shrinking and loses money

17.5%of US adults took last season's COVID shot
$2.93Blost from operations over twelve months to September 2026
Halfof any cancer vaccine profit goes to Merck

Listed rivals: PFE · BNTX · NVAX · SNY · GSK · MRK

Pfizer and BioNTech sell the larger COVID shot, GSK and Pfizer reached older adults with RSV vaccines first, and few people still want a yearly booster.

Is it a good business? · 6 · What does its record show?

Sales fell nine-tenths from the pandemic peak

Sales, $B
18.5
19.3
6.8
3.2
1.9
2.5
Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025last 12 mo
Sales then$19.3B2022, at the pandemic peak
Sales now$1.9B2025
Latest growth29%third quarter of 2026, a year earlier

Moderna cut research from $4.5B in 2024 to $3.1B in 2025 and expects 2026 sales to grow 15% to 25%. It still loses money over a full year.

Is it a good business? · 7 · How much room is there to grow?

Melanoma alone could be a business of a few billion dollars

112,000Americans expected to be found with melanoma in 2026
About 11,000of them with cancer in nearby lymph nodes, like the trial's patients
About $217,000a year of Keytruda at list price, the yardstick for a new cancer medicine

At full use that is about $2.4B a year in the US, before Merck takes half. Lung cancer, if its trial works, would be far bigger.

Is it a good business? · 8 · Who is in charge?

The long-time chief executive owns 7.6% of the company

Stéphane Bancelchief executive since 2011
7.6%of the shares he owns
1,073,172shares insiders sold in a year, nearly all under plans set in advance

He led Moderna through the pandemic boom and the fall, then cut costs. A new operating chief returned in October 2026 to run manufacturing for the cancer vaccine launch.

The story right now · 9 · How does a personalised cancer vaccine work?

Each patient's dose is built from their own tumour

  1. The tumour is removedSurgery takes it out, and it is read for mutations.
  2. Software picks the targetsUp to 34 mutations the immune system can spot.
  3. One dose made per patientThe goal is about six weeks from surgery.
  4. Every patient is a new batchSlow or costly making limits how many are treated.

Given with Keytruda, the dose teaches the immune system to hunt any cancer cells left behind, so fewer cancers come back.

The story right now · 10 · What changed lately?

A trial success sent the shares soaring, then the full data cooled them

19 Aug 2026the melanoma trial succeeded; the shares nearly tripled that day
22 Oct 2026the full data leaked early; the shares fell about a sixth
End of 2026Moderna plans to ask for US approval

Solid quarter

Lung, kidney and bladder cancer trials are fully enrolled. The third quarter brought a rare profit, but the year will still be a large loss.

The story right now · 11 · What is everyone arguing about?

Is this a one-cancer success, or a platform for many?

Many investors think

The cancer vaccine works, so Moderna is now a cancer company worth paying up for

We think

It has worked in one cancer; Merck takes half, and the price already pays for success in many

We would be wrong if the lung cancer trial succeeds and the launch is priced near a year of Keytruda. Survival benefits are not yet shown.

The price and our view · 12 · What is a share worth?

The price sits far above even our sunny future

$38.97what we think a share is worth
$38.97our value
Attractive
below $31.18
Unattractive
above $46.76
$16.70gloomy: the launch is slow and vaccines keep shrinking
$38.97our estimate: sales follow the experts' forecasts
$78.13sunny: cancer sales spread faster and further

Value per share in three futures. None is a prediction of the share price.

We estimate what a share is worth from forecasts that already include the cancer vaccine's launch. Even the sunny case is far below today's price.

The price and our view · 13 · What if it all works?

A big cancer win would pay for only a slice of the price

Priced for successthe kind of bet this is
0.2×if it works
12%kept if it fails

Multiples of the company's value when the bet was last struck, 16 Nov 2026.

We also ask what you get if the cancer vaccine succeeds, and what is left if it fails. Success in melanoma adds little at this price; failure leaves a shrinking vaccine business.

The price and our view · 14 · How could we be wrong?

The biggest danger is that one cancer is all it works in

Lung cancer missesBiggest

Most of the price rests on the vaccine spreading.

Survival not shownUnknown

Insurers may not pay without longer lives.

Vaccines keep shrinkingShowing now

Fewer people take a yearly COVID shot.

Making each doseWatch

Slow manufacturing would limit patients treated.

Patent fights cut both ways: Moderna paid $950M to settle one suit and still sues Pfizer and BioNTech.

The price and our view · 15 · How will we know?

The approval filing and the next trials show how far it reaches

The US accepts the approval filing for melanomaGood sign
The lung cancer trial shows fewer cancers coming backGood sign
The kidney cancer trial disappoints, or the filing slipsBad sign
FEB 202712

Results for the last quarter of 2026. Companies report every three months; this one should say whether the filing went in.

Our view also changes on price alone: if the shares fall to within a fifth of our estimate, we move to Neutral.

The price and our view · 16 · So, what do we think?

A real cancer result, priced as if it had already won everywhere

$38.97our value
Attractive
below $31.18
Unattractive
above $46.76

UnattractiveHigh conviction

The melanoma result is real. But Merck keeps half, the vaccines keep shrinking, and the price is far above even our sunny estimate. Unattractive is about the price, not the science.

↑ ↓ to move · C for contents